S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Legendary Stockpicker: "Buy this A.I. stock NOW" (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
Better Than Oil Stocks? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Forecast, Price & News

$13.57
-0.14 (-1.02%)
(As of 09/29/2023 ET)
Compare
Today's Range
$13.19
$13.82
50-Day Range
$12.90
$17.45
52-Week Range
$12.29
$30.79
Volume
34,667 shs
Average Volume
68,723 shs
Market Capitalization
$375.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00

Aerovate Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
172.7% Upside
$37.00 Price Target
Short Interest
Bearish
8.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Aerovate Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$750,605 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.82) to ($2.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

789th out of 970 stocks

Pharmaceutical Preparations Industry

374th out of 450 stocks


AVTE stock logo

About Aerovate Therapeutics (NASDAQ:AVTE) Stock

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

AVTE Price History

AVTE Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
TENX: Notice of Allowance Increases Confidence
8-K: Aerovate Therapeutics, Inc.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Aerovate Therapeutics (AVTE) Receives a Buy from Wedbush
12 Best Performing Biotech Stocks in 2022
See More Headlines
Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTE Company Calendar

Last Earnings
8/14/2023
Today
9/30/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVTE
Fax
N/A
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.00
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+172.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.19 per share

Miscellaneous

Free Float
22,314,000
Market Cap
$375.21 million
Optionable
Not Optionable
Beta
0.37
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Timothy P. Noyes M.B.A. (Age 61)
    CEO & Director
    Comp: $703.8k
  • Mr. George A. Eldridge (Age 60)
    CFO & Treasurer
    Comp: $533.89k
  • Dr. Marinus Verwijs Ph.D. (Age 47)
    Chief Technical Officer
    Comp: $439.88k
  • Dr. Benjamin T. Dake Ph.D. (Age 47)
    Founder, Pres, COO & Sec.
  • Dr. Ralph W. Niven M.B.A. (Age 63)
    M.R, Ph.D., Pharm.S, Chief Scientific Officer
  • Mr. Hunter Gillies M.D. (Age 57)
    Chief Medical Officer
  • Mr. Timothy J. Pigot (Age 52)
    Chief Commercial Officer
  • Ms. Donna Dea
    Head of Regulatory Affairs
  • Ms. Susan Fischer
    Sr. VP of Devel. Operations
  • Mr. Stephen K. Yu
    Sr. VP of Quality













AVTE Stock - Frequently Asked Questions

Should I buy or sell Aerovate Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVTE shares.
View AVTE analyst ratings
or view top-rated stocks.

What is Aerovate Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 12 month target prices for Aerovate Therapeutics' shares. Their AVTE share price forecasts range from $27.00 to $48.00. On average, they predict the company's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price.
View analysts price targets for AVTE
or view top-rated stocks among Wall Street analysts.

How have AVTE shares performed in 2023?

Aerovate Therapeutics' stock was trading at $29.30 at the beginning of 2023. Since then, AVTE shares have decreased by 53.7% and is now trading at $13.57.
View the best growth stocks for 2023 here
.

Are investors shorting Aerovate Therapeutics?

Aerovate Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,430,000 shares, an increase of 5.9% from the August 31st total of 1,350,000 shares. Based on an average trading volume of 71,500 shares, the days-to-cover ratio is currently 20.0 days. Approximately 8.3% of the company's shares are sold short.
View Aerovate Therapeutics' Short Interest
.

When is Aerovate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our AVTE earnings forecast
.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.07.

When did Aerovate Therapeutics IPO?

(AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

What is Aerovate Therapeutics' stock symbol?

Aerovate Therapeutics trades on the NASDAQ under the ticker symbol "AVTE."

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerovate Therapeutics' stock price today?

One share of AVTE stock can currently be purchased for approximately $13.57.

How much money does Aerovate Therapeutics make?

Aerovate Therapeutics (NASDAQ:AVTE) has a market capitalization of $375.21 million. The company earns $-51,510,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How can I contact Aerovate Therapeutics?

The official website for the company is aerovatetx.com. The company can be reached via phone at 617-443-2400 or via email at ir@aerovatetx.com.

This page (NASDAQ:AVTE) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -